Joanna Glasner Contributor More posts by this contributor While tech waffles on going public, biotech IPOs boom Shoe startups aren’t dragging their feet Startup exit tallies commonly underestimate biotech returns. Unlike most tech deals, the biggest profits in bio often come long after an IPO or acquisition. Take Juno Therapeutics, a publicly traded cancer immunology company […]